Skip to main content
ICD-10-PCS/XW0
ICD-10-PCS Table

XW0

New Technology, Anatomical Regions, Introduction

Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

178 codes total in this table

Axis Grid

Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 1Daratumumab and Hyaluronidase-fihj
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW01318
Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 2Talquetamab Antineoplastic
New Technology Group
  • 9New Technology Group 9
1 code in this combination
XW01329
Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 4Teclistamab Antineoplastic
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW01348
Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 4Elamipretide
New Technology Group
  • CNew Technology Group 12
1 code in this combination
XW0134C
Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 6Dasiglucagon
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW0136A
Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • FOther New Technology Therapeutic Substance
New Technology Group
  • 5New Technology Group 5
1 code in this combination
XW013F5
Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • GREGN-COV2 Monoclonal Antibody
  • HOther New Technology Monoclonal Antibody
  • KLeronlimab Monoclonal Antibody
New Technology Group
  • 6New Technology Group 6
3 codes in this combination
XW013G6XW013H6XW013K6
Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • LElranatamab Antineoplastic
New Technology Group
  • 9New Technology Group 9
1 code in this combination
XW013L9
Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • SCOVID-19 Vaccine Dose 1
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW013S6
Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • SEpcoritamab Monoclonal Antibody
New Technology Group
  • 9New Technology Group 9
1 code in this combination
XW013S9
Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • TCOVID-19 Vaccine Dose 2
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW013T6
Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • TRozanolixizumab-noli Monoclonal Antibody
New Technology Group
  • BNew Technology Group 11
1 code in this combination
XW013TB
Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • UCOVID-19 Vaccine
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW013U6
Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • VCOVID-19 Vaccine Dose 3
New Technology Group
  • 7New Technology Group 7
1 code in this combination
XW013V7
Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • WCaplacizumab
New Technology Group
  • 5New Technology Group 5
1 code in this combination
XW013W5
Body Part
  • 1Subcutaneous Tissue
Approach
  • 3Percutaneous
Device / Substance / Technology
  • WCOVID-19 Vaccine Booster
New Technology Group
  • 7New Technology Group 7
1 code in this combination
XW013W7
Body Part
  • 2Muscle
Approach
  • 0Open
Device / Substance / Technology
  • DEngineered Allogeneic Thymus Tissue
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW020D8
Body Part
  • 2Muscle
Approach
  • 3Percutaneous
Device / Substance / Technology
  • SCOVID-19 Vaccine Dose 1
  • TCOVID-19 Vaccine Dose 2
  • UCOVID-19 Vaccine
New Technology Group
  • 6New Technology Group 6
3 codes in this combination
XW023S6XW023T6XW023U6
Body Part
  • 2Muscle
Approach
  • 3Percutaneous
Device / Substance / Technology
  • VCOVID-19 Vaccine Dose 3
  • WCOVID-19 Vaccine Booster
  • YOther New Technology Monoclonal Antibody
New Technology Group
  • 7New Technology Group 7
3 codes in this combination
XW023V7XW023W7XW023Y7
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 0Spesolimab Monoclonal Antibody
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW03308
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 0Alpha1-proteinase Inhibitor
  • 1Anitocabtagene Autoleucel Immunotherapy
New Technology Group
  • BNew Technology Group 11
2 codes in this combination
XW0330BXW0331B
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 3Bentracimab, Ticagrelor Reversal Agent
  • 4Cefepime-taniborbactam Anti-infective
New Technology Group
  • ANew Technology Group 10
2 codes in this combination
XW0333AXW0334A
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 5Narsoplimab Monoclonal Antibody
New Technology Group
  • 7New Technology Group 7
1 code in this combination
XW03357
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 5Mosunetuzumab Antineoplastic
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW03358
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 5Ceftobiprole Medocaril Anti-infective
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW0335A
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 6Afamitresgene Autoleucel Immunotherapy
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW03368
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 6Landiolol Antiarrhythmic
New Technology Group
  • CNew Technology Group 12
1 code in this combination
XW0336C
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 7Coagulation Factor Xa, Inactivated
New Technology Group
  • 2New Technology Group 2
1 code in this combination
XW03372
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 7Tabelecleucel Immunotherapy
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW03378
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 7Zimislecel Allogeneic Stem Cell-Derived Islet Cell Therapy
New Technology Group
  • CNew Technology Group 12
1 code in this combination
XW0337C
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 8Treosulfan
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW03388
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 8Obecabtagene Autoleucel
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW0338A
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 9Ceftolozane/Tazobactam Anti-infective
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW03396
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 9Inebilizumab-cdon
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW03398
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 9Odronextamab Antineoplastic
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW0339A
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • ACiltacabtagene Autoleucel
New Technology Group
  • 7New Technology Group 7
1 code in this combination
XW033A7
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • BCytarabine and Daunorubicin Liposome Antineoplastic
New Technology Group
  • 3New Technology Group 3
1 code in this combination
XW033B3
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • BOrca-T Allogeneic T-cell Immunotherapy
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW033BA
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • CEngineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
New Technology Group
  • 7New Technology Group 7
1 code in this combination
XW033C7
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • CZanidatamab Antineoplastic
  • DDonislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension
New Technology Group
  • ANew Technology Group 10
2 codes in this combination
XW033CAXW033DA
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • ERemdesivir Anti-infective
New Technology Group
  • 5New Technology Group 5
1 code in this combination
XW033E5
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • FOther New Technology Therapeutic Substance
New Technology Group
  • 3New Technology Group 3
1 code in this combination
XW033F3
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • FOther New Technology Therapeutic Substance
New Technology Group
  • 5New Technology Group 5
1 code in this combination
XW033F5
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • FNon-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW033FA
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • FValoctocogene Roxaparvovec-rvox
New Technology Group
  • BNew Technology Group 11
1 code in this combination
XW033FB
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • GSarilumab
New Technology Group
  • 5New Technology Group 5
1 code in this combination
XW033G5
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • GREGN-COV2 Monoclonal Antibody
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW033G6
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • GEngineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
New Technology Group
  • 7New Technology Group 7
1 code in this combination
XW033G7
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • HTocilizumab
New Technology Group
  • 5New Technology Group 5
1 code in this combination
XW033H5
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • HOther New Technology Monoclonal Antibody
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW033H6
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • HAxicabtagene Ciloleucel Immunotherapy
  • JTisagenlecleucel Immunotherapy
  • KIdecabtagene Vicleucel Immunotherapy
New Technology Group
  • 7New Technology Group 7
3 codes in this combination
XW033H7XW033J7XW033K7
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • KSulbactam-Durlobactam
New Technology Group
  • 9New Technology Group 9
1 code in this combination
XW033K9
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • LCD24Fc Immunomodulator
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW033L6
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • LLifileucel Immunotherapy
  • MBrexucabtagene Autoleucel Immunotherapy
New Technology Group
  • 7New Technology Group 7
2 codes in this combination
XW033L7XW033M7
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • MEmapalumab-lzsg Anti-IFNy Monoclonal Antibody
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW033MA
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • NLisocabtagene Maraleucel Immunotherapy
New Technology Group
  • 7New Technology Group 7
1 code in this combination
XW033N7
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • NTarlatamab-dlle Antineoplastic
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW033NA
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • PGlofitamab Antineoplastic
New Technology Group
  • 9New Technology Group 9
1 code in this combination
XW033P9
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • PAztreonam-avibactam Anti-infective
New Technology Group
  • BNew Technology Group 11
1 code in this combination
XW033PB
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • QTagraxofusp-erzs Antineoplastic
New Technology Group
  • 5New Technology Group 5
1 code in this combination
XW033Q5
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • QPosoleucel
New Technology Group
  • 9New Technology Group 9
1 code in this combination
XW033Q9
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • QIloprost
New Technology Group
  • BNew Technology Group 11
1 code in this combination
XW033QB
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • RRezafungin
New Technology Group
  • 9New Technology Group 9
1 code in this combination
XW033R9
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • RLetetresgene Autoleucel
New Technology Group
  • BNew Technology Group 11
1 code in this combination
XW033RB
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • SIobenguane I-131 Antineoplastic
  • WCaplacizumab
New Technology Group
  • 5New Technology Group 5
2 codes in this combination
XW033S5XW033W5
Body Part
  • 3Peripheral Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • WFosfomycin Anti-infective
New Technology Group
  • BNew Technology Group 11
1 code in this combination
XW033WB
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 0Spesolimab Monoclonal Antibody
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW04308
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 0Alpha1-proteinase Inhibitor
  • 1Anitocabtagene Autoleucel Immunotherapy
New Technology Group
  • BNew Technology Group 11
2 codes in this combination
XW0430BXW0431B
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 3Bentracimab, Ticagrelor Reversal Agent
  • 4Cefepime-taniborbactam Anti-infective
New Technology Group
  • ANew Technology Group 10
2 codes in this combination
XW0433AXW0434A
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 5Narsoplimab Monoclonal Antibody
New Technology Group
  • 7New Technology Group 7
1 code in this combination
XW04357
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 5Mosunetuzumab Antineoplastic
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW04358
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 5Ceftobiprole Medocaril Anti-infective
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW0435A
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 6Afamitresgene Autoleucel Immunotherapy
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW04368
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 6Landiolol Antiarrhythmic
New Technology Group
  • CNew Technology Group 12
1 code in this combination
XW0436C
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 7Coagulation Factor Xa, Inactivated
New Technology Group
  • 2New Technology Group 2
1 code in this combination
XW04372
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 7Tabelecleucel Immunotherapy
  • 8Treosulfan
New Technology Group
  • 8New Technology Group 8
2 codes in this combination
XW04378XW04388
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 8Obecabtagene Autoleucel
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW0438A
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 9Ceftolozane/Tazobactam Anti-infective
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW04396
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 9Inebilizumab-cdon
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW04398
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 9Odronextamab Antineoplastic
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW0439A
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • ACiltacabtagene Autoleucel
New Technology Group
  • 7New Technology Group 7
1 code in this combination
XW043A7
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • BCytarabine and Daunorubicin Liposome Antineoplastic
New Technology Group
  • 3New Technology Group 3
1 code in this combination
XW043B3
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • BOrca-T Allogeneic T-cell Immunotherapy
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW043BA
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • CEngineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
New Technology Group
  • 7New Technology Group 7
1 code in this combination
XW043C7
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • CZanidatamab Antineoplastic
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW043CA
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • ERemdesivir Anti-infective
New Technology Group
  • 5New Technology Group 5
1 code in this combination
XW043E5
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • FOther New Technology Therapeutic Substance
New Technology Group
  • 3New Technology Group 3
1 code in this combination
XW043F3
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • FOther New Technology Therapeutic Substance
New Technology Group
  • 5New Technology Group 5
1 code in this combination
XW043F5
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • FNon-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW043FA
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • FValoctocogene Roxaparvovec-rvox
New Technology Group
  • BNew Technology Group 11
1 code in this combination
XW043FB
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • GSarilumab
New Technology Group
  • 5New Technology Group 5
1 code in this combination
XW043G5
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • GREGN-COV2 Monoclonal Antibody
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW043G6
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • GEngineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
New Technology Group
  • 7New Technology Group 7
1 code in this combination
XW043G7
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • HTocilizumab
New Technology Group
  • 5New Technology Group 5
1 code in this combination
XW043H5
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • HOther New Technology Monoclonal Antibody
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW043H6
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • HAxicabtagene Ciloleucel Immunotherapy
  • JTisagenlecleucel Immunotherapy
  • KIdecabtagene Vicleucel Immunotherapy
New Technology Group
  • 7New Technology Group 7
3 codes in this combination
XW043H7XW043J7XW043K7
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • KSulbactam-Durlobactam
New Technology Group
  • 9New Technology Group 9
1 code in this combination
XW043K9
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • LCD24Fc Immunomodulator
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW043L6
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • LLifileucel Immunotherapy
  • MBrexucabtagene Autoleucel Immunotherapy
New Technology Group
  • 7New Technology Group 7
2 codes in this combination
XW043L7XW043M7
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • MEmapalumab-lzsg Anti-IFNy Monoclonal Antibody
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW043MA
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • NLisocabtagene Maraleucel Immunotherapy
New Technology Group
  • 7New Technology Group 7
1 code in this combination
XW043N7
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • NTarlatamab-dlle Antineoplastic
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW043NA
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • PGlofitamab Antineoplastic
New Technology Group
  • 9New Technology Group 9
1 code in this combination
XW043P9
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • PAztreonam-avibactam Anti-infective
New Technology Group
  • BNew Technology Group 11
1 code in this combination
XW043PB
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • QTagraxofusp-erzs Antineoplastic
New Technology Group
  • 5New Technology Group 5
1 code in this combination
XW043Q5
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • QPosoleucel
New Technology Group
  • 9New Technology Group 9
1 code in this combination
XW043Q9
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • QIloprost
New Technology Group
  • BNew Technology Group 11
1 code in this combination
XW043QB
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • RRezafungin
New Technology Group
  • 9New Technology Group 9
1 code in this combination
XW043R9
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • RLetetresgene Autoleucel
New Technology Group
  • BNew Technology Group 11
1 code in this combination
XW043RB
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • SIobenguane I-131 Antineoplastic
  • WCaplacizumab
New Technology Group
  • 5New Technology Group 5
2 codes in this combination
XW043S5XW043W5
Body Part
  • 4Central Vein
Approach
  • 3Percutaneous
Device / Substance / Technology
  • WFosfomycin Anti-infective
New Technology Group
  • BNew Technology Group 11
1 code in this combination
XW043WB
Body Part
  • 5Peripheral Artery
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 4Stem Cells, Somatic
New Technology Group
  • BNew Technology Group 11
1 code in this combination
XW0534B
Body Part
  • 5Peripheral Artery
Approach
  • 3Percutaneous
Device / Substance / Technology
  • TMelphalan Hydrochloride Antineoplastic
New Technology Group
  • 9New Technology Group 9
1 code in this combination
XW053T9
Body Part
  • 6Cerebral Ventricle
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 2CPI-601 Enzyme Replacement Therapy
New Technology Group
  • BNew Technology Group 11
1 code in this combination
XW0632B
Body Part
  • DMouth and Pharynx
Approach
  • XExternal
Device / Substance / Technology
  • 3Maribavir Anti-infective
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW0DX38
Body Part
  • DMouth and Pharynx
Approach
  • XExternal
Device / Substance / Technology
  • 8Uridine Triacetate
New Technology Group
  • 2New Technology Group 2
1 code in this combination
XW0DX82
Body Part
  • DMouth and Pharynx
Approach
  • XExternal
Device / Substance / Technology
  • FOther New Technology Therapeutic Substance
New Technology Group
  • 5New Technology Group 5
1 code in this combination
XW0DXF5
Body Part
  • DMouth and Pharynx
Approach
  • XExternal
Device / Substance / Technology
  • JQuizartinib Antineoplastic
New Technology Group
  • 9New Technology Group 9
1 code in this combination
XW0DXJ9
Body Part
  • DMouth and Pharynx
Approach
  • XExternal
Device / Substance / Technology
  • KSabizabulin
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW0DXK8
Body Part
  • DMouth and Pharynx
Approach
  • XExternal
Device / Substance / Technology
  • MBaricitinib
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW0DXM6
Body Part
  • DMouth and Pharynx
Approach
  • XExternal
Device / Substance / Technology
  • NSER-109
New Technology Group
  • 9New Technology Group 9
1 code in this combination
XW0DXN9
Body Part
  • DMouth and Pharynx
Approach
  • XExternal
Device / Substance / Technology
  • VXanomeline and Trospium Chloride
New Technology Group
  • BNew Technology Group 11
1 code in this combination
XW0DXVB
Body Part
  • EEar(s)
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 3Lunsotogene Parvec-cwha via Intracochlear Infusion
New Technology Group
  • BNew Technology Group 11
1 code in this combination
XW0E33B
Body Part
  • GUpper GI
Approach
  • 7Via Natural or Artificial Opening
Device / Substance / Technology
  • 3Maribavir Anti-infective
  • KSabizabulin
New Technology Group
  • 8New Technology Group 8
2 codes in this combination
XW0G738XW0G7K8
Body Part
  • GUpper GI
Approach
  • 7Via Natural or Artificial Opening
Device / Substance / Technology
  • MBaricitinib
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW0G7M6
Body Part
  • GUpper GI
Approach
  • 8Via Natural or Artificial Opening Endoscopic
Device / Substance / Technology
  • 8Mineral-based Topical Hemostatic Agent
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW0G886
Body Part
  • HLower GI
Approach
  • 7Via Natural or Artificial Opening
Device / Substance / Technology
  • 3Maribavir Anti-infective
  • KSabizabulin
New Technology Group
  • 8New Technology Group 8
2 codes in this combination
XW0H738XW0H7K8
Body Part
  • HLower GI
Approach
  • 7Via Natural or Artificial Opening
Device / Substance / Technology
  • MBaricitinib
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW0H7M6
Body Part
  • HLower GI
Approach
  • 7Via Natural or Artificial Opening
Device / Substance / Technology
  • XBroad Consortium Microbiota-based Live Biotherapeutic Suspension
New Technology Group
  • 8New Technology Group 8
1 code in this combination
XW0H7X8
Body Part
  • HLower GI
Approach
  • 8Via Natural or Artificial Opening Endoscopic
Device / Substance / Technology
  • 8Mineral-based Topical Hemostatic Agent
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW0H886
Body Part
  • JCoronary Artery, One Artery
  • KCoronary Artery, Two Arteries
  • LCoronary Artery, Three Arteries
  • MCoronary Artery, Four or More Arteries
Approach
  • 3Percutaneous
Device / Substance / Technology
  • HPaclitaxel-Coated Balloon Technology, One Balloon
  • JPaclitaxel-Coated Balloon Technology, Two Balloons
  • KPaclitaxel-Coated Balloon Technology, Three Balloons
  • LPaclitaxel-Coated Balloon Technology, Four or More Balloons
New Technology Group
  • ANew Technology Group 10
16 codes in this combination
XW0J3HAXW0J3JAXW0J3KAXW0J3LAXW0K3HAXW0K3JAXW0K3KAXW0K3LAXW0L3HAXW0L3JAXW0L3KAXW0L3LAXW0M3HAXW0M3JAXW0M3KAXW0M3LA
Body Part
  • QCranial Cavity and Brain
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 1Eladocagene exuparvovec
New Technology Group
  • 6New Technology Group 6
1 code in this combination
XW0Q316
Body Part
  • QCranial Cavity and Brain
Approach
  • 3Percutaneous
Device / Substance / Technology
  • 5Ifezuntirgene Inilparvovec
New Technology Group
  • CNew Technology Group 12
1 code in this combination
XW0Q35C
Body Part
  • UJoints
Approach
  • 0Open
Device / Substance / Technology
  • CRecombinant Human Bone Morphogenetic Protein-2 with Collagen Scaffold
New Technology Group
  • CNew Technology Group 12
1 code in this combination
XW0U0CC
Body Part
  • UJoints
Approach
  • 0Open
Device / Substance / Technology
  • GVancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW0U0GA
Body Part
  • UJoints
Approach
  • 0Open
  • 3Percutaneous
  • 4Percutaneous Endoscopic
Device / Substance / Technology
  • XPeptide Enhanced Bone Void Filler
New Technology Group
  • BNew Technology Group 11
3 codes in this combination
XW0U0XBXW0U3XBXW0U4XB
Body Part
  • VBones
Approach
  • 0Open
Device / Substance / Technology
  • BVancomycin-eluting Bone Void Filler
New Technology Group
  • CNew Technology Group 12
1 code in this combination
XW0V0BC
Body Part
  • VBones
Approach
  • 0Open
Device / Substance / Technology
  • PGentamicin-eluting Bone Void Filler
New Technology Group
  • 7New Technology Group 7
1 code in this combination
XW0V0P7
Body Part
  • VBones
Approach
  • 3Percutaneous
Device / Substance / Technology
  • WAGN1 Bone Void Filler
New Technology Group
  • ANew Technology Group 10
1 code in this combination
XW0V3WA